Unknown

Dataset Information

0

The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.


ABSTRACT: The design, synthesis and biological evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported. Four compounds (11-13, 15) inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor ? (PDGFR-?), and target tubulin leading to cytotoxicity. Compound 11 has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-?. Further, 11 binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both ?III-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis. In vivo, its HCl salt, 21, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity. Thus 21 affords potential combination chemotherapy in a single agent.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC4089508 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Zhang Xin X   Raghavan Sudhir S   Ihnat Michael M   Thorpe Jessica E JE   Disch Bryan C BC   Bastian Anja A   Bailey-Downs Lora C LC   Dybdal-Hargreaves Nicholas F NF   Rohena Cristina C CC   Hamel Ernest E   Mooberry Susan L SL   Gangjee Aleem A  

Bioorganic & medicinal chemistry 20140514 14


The design, synthesis and biological evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported. Four compounds (11-13, 15) inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity. Compound 11 has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β. Further, 11 binds at the colchicine site on tubulin,  ...[more]

Similar Datasets

| S-EPMC4410085 | biostudies-literature
| S-EPMC3138178 | biostudies-literature
| S-EPMC5590101 | biostudies-literature
| S-EPMC4714715 | biostudies-literature
| S-EPMC8747035 | biostudies-literature
| S-EPMC3853131 | biostudies-literature
| S-EPMC3310894 | biostudies-literature
| S-EPMC7875120 | biostudies-literature
| S-EPMC9972360 | biostudies-literature
| S-EPMC2739130 | biostudies-literature